Plasma growth hormone and insulin response to levodopa and amantadine

1973 ◽  
Vol 34 (2) ◽  
pp. 145-151 ◽  
Author(s):  
O. Kyt�m�ki ◽  
R. Nousiainen ◽  
A. Pekkarinen ◽  
U. K. Rinne ◽  
M. Viljanen
Keyword(s):  
Growth Hormone ◽  
Insulin Response ◽  
Plasma Growth Hormone

Glucose tolerance, growth hormone and somatomedin levels in osteosarcoma patients

1980 ◽  
Vol 94 (4) ◽  
pp. 517-522 ◽  
Author(s):  
U. Adamson ◽  
L.-Å. Broström ◽  
S. Efendić ◽  
K. Hall
Keyword(s):  
Growth Hormone ◽  
Glucose Tolerance ◽  
Insulin Response ◽  
Plasma Growth Hormone ◽  
Intravenous Glucose ◽  
Insulin Response To Glucose ◽  
The Mean ◽  
The Individual ◽  
And Control ◽  
Mean Glucose

Abstract. Intravenous glucose tolerance, insulin response to glucose, the sensitivity of the periphery to insulin as well as growth hormone and somatomedin levels were determined in osteosarcoma patients and control subjects matched by age, sex, weight and length. The insulin response to glucose and the peripheral sensitivity to insulin were evaluated by using the individual blood glucose and plasma insulin curves for parameter identification in a mathematical model. The mean glucose tolerance was significantly decreased in the patients, most likely due to decreased peripheral insulin sensitivity. Plasma growth hormone levels were normal in all patients which was also the case with somatomedin levels determined by both radioreceptor- and radioimmunoassay.

Influence of medroxyprogesterone acetate (Provera) on plasma growth hormone levels and on carbohydrate metabolism

1981 ◽  
Vol 98 (4) ◽  
pp. 603-608 ◽  
Author(s):  
J. E. Eigenmann ◽  
R. Y Eigenmann
Keyword(s):  
Insulin Resistance ◽  
Growth Hormone ◽  
Carbohydrate Metabolism ◽  
Medroxyprogesterone Acetate ◽  
Insulin Response ◽  
The Other ◽  
Combined Effects ◽  
Glucose Load ◽  
Plasma Growth Hormone ◽  
Glucose Assimilation

Abstract. The combined effects of oestradiol and medroxyprogesterone acetate on growth hormone (GH) levels and carbohydrate metabolism were studied in 6 ovariohysterectomized dogs, which previously had shown moderate increments in GH after medroxyprogesterone acetate (MPA) administration. Oestradiol (Oe2) implants were administered 5 months after the last MPA injection, when MPA and GH levels tended to decrease. Following Oe2 administration GH levels rose significantly. Single MPA injections (100 mg) given 20 days after Oe2-priming were followed by still further increased GH levels. These GH levels were several-fold higher than GH levels achieved by previous MPA administration alone. GH levels decreased in 3 dogs after 35 days and remained elevated in the other 3 dogs as long as 70 days after MPA administration with Oe2 priming. Glucose assimilation became impaired and insulin response to a glucose load increased in relation to elevated GH levels. Oe2-primed control dogs, which received no MPA, failed to develop elevated GH levels. These findings indicate (1) that Oe2 and MPA induce overproduction in ovariohysterectomized dogs synergistically (2) that GH levels of the magnitude evoked are associated with glucose intolerance and insulin resistance.

Single and repeated testing of growth hormone secretory capacity in hypopituitarism using growth hormone releasing factor

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S118-S122 ◽  
Author(s):  
O. BUTENANDT ◽  
M. EMMLINGER ◽  
H. DOERR
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Pituitary Gland ◽  
Bolus Injection ◽  
Hormone Deficiency ◽  
Test Results ◽  
Repeated Testing ◽  
Plasma Growth Hormone ◽  
Once Daily ◽  
Secretory Capacity

Abstract 38 patients with proven growth hormone deficiency (GHD) and 19 children with familial short stature received an iv GRF-bolus injection of 1 ug/kg body weight. Whereas in all control children plasma growth hormone rose significantly (mean of maximal values 36 ng/ml), only 7 out of 38 patients with GHD reached peak values of 8 ng/ml or more. GRF-priming by 1 ug GRF/kg BW given once daily s.c. for 5 days in 19 patients improved the response of the pituitary gland in 11. Thus, following the first GRF test, only 21 % of patients demonstrated function of the pituitary gland whereas 45 % did so when all test results are combined. To evaluate the pituitary function in patients with GHD correctly, GRF tests following a GRF priming period seems to be necessary to reactivate atrophic somatotropic cells of the pituitary gland.

Effect of Growth Hormone-Releasing Factor on Plasma Growth Hormone, Prolactin and Somatomedin C in Hypopituitary and Short Normal Children

1985 ◽  
Vol 22 (1-2) ◽  
pp. 32-45 ◽  
Author(s):  
Guy Van Vliet ◽  
Danièle Bosson ◽  
Claude Robyn ◽  
Margareta Craen ◽  
Paul Malvaux ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Plasma Growth Hormone ◽  
Normal Children ◽  
Somatomedin C ◽  
Growth Hormone Releasing Factor

CHANGES IN PLASMA GROWTH HORMONE LEVELS IN RETARDED CHILDREN

2008 ◽  
Vol 12 (3-4) ◽  
pp. 294-306
Author(s):  
J. HILLMAN ◽  
J. HAMMOND ◽  
J. SOKOLA ◽  
M. REISS
Keyword(s):  
Growth Hormone ◽  
Plasma Growth Hormone ◽  
Hormone Levels

Variation in plasma growth hormone during first parity in lactating cows1

2007 ◽  
Vol 85 (2) ◽  
pp. 388-394 ◽  
Author(s):  
P. Theilgaard ◽  
K. L. Ingvartsen ◽  
P. Løvendahl
Keyword(s):  
Growth Hormone ◽  
Plasma Growth Hormone
Sign in / Sign up

Export Citation Format

Share Document